Clinical Trial Update: Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab [Phase 2]

View source ↗

Summary

This update reports the results of a Phase 2 trial evaluating the combination of cladribine and rituximab for hairy cell leukemia and its variant, including rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia
• Hairy Cell Leukemia Variant

Drugs mentioned

• Leustatin (cladribine)
• Rituxan (rituximab)

Snippet

Sponsor: Jurgen Barth | Conditions: Hairy Cell Leukemia (HCL) | Phase 2 | Status: COMPLETED